Insiders Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-18 pm EDT			5-day change	1st Jan Change
15.55 ^USD	+3.39%		-0.45%	-40.60%

May. 16	Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	CI
May. 13	Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	Jan. 31	MT
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	Dec. 14	CI
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	Nov. 30	CI
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing	23-10-27	MT
Tourmaline Bio Insider Bought Shares Worth $110,912, According to a Recent SEC Filing	23-10-26	MT
Insider Sell: Talaris Therapeutics	23-06-15	MT
Insider Sell: Talaris Therapeutics	23-06-09	MT
Talaris Therapeutics Names Mary Kay Fenton Interim Chief Executive	23-05-26	MT
Talaris Therapeutics, Inc. Announces Executive Changes	23-05-26	CI
Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as President	23-05-26	CI
Insider Sell: Talaris Therapeutics	23-04-21	MT
Insider Sell: Talaris Therapeutics	23-04-19	MT
Talaris Therapeutics, Inc. Announces the Resignation of Scott Requadt as Chief Executive Officer, Effective May 26, 2023	23-04-14	CI
Talaris Therapeutics, Inc. Announces Executive Resignation	23-04-14	CI
Insider Sell: Talaris Therapeutics	22-08-24	MT
Talaris Therapeutics, Inc. Announces Transition of Suzanne Ildstad as CSO to Being A Senior Scientific Advisor, Effective to Being A Senior Scientific Advisor	22-08-15	CI
Insider Buy: Talaris Therapeutics	22-08-02	MT
Talaris Therapeutics, Inc. Announces Board Changes	22-05-17	CI
Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as Chief Financial Officer	21-03-04	CI
Talaris Therapeutics, Inc. Announces Board and Committee Appointments	21-01-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Insiders

Filters